Sedogen

Sedogen Therapeutics is a biotechnology company developing first-in-class therapeutics for metabolic and inflammatory diseases by targeting the sedoheptulose kinase (SHPK) pathway. Founded on the research of Dr. Gökhan Hotamisligil at the Harvard T.H. Chan School of Public Health, the company focuses on the intersection of metabolism and immune function, known as immunometabolism. Their lead programs involve small molecule modulators designed to restore metabolic homeostasis in conditions such as metabolic dysfunction-associated steatohepatitis (MASH), obesity, and type 2 diabetes. Sedogen is currently in the pre-clinical stage, leveraging deep insights into the pentose phosphate pathway to address significant unmet needs in chronic metabolic health. The company aims to translate complex biological mechanisms into transformative medicines for patients worldwide.